Madrigal Pharmaceuticals is an innovative clinical-stage biopharmaceutical company with a clear goal: find a viable treatment for non-alcoholic steatohepatitis (NASH) in the United States. With its focus squarely on developing therapeutics to combat this debilitating disease, the company's lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is presently in Phase III clinical trials to gauge its effectiveness in managing NASH. Furthermore, Madrigal Pharmaceuticals is also working hard on creating MGL-3745, a backup compound to resmetirom. The company's headquarters are based in the dynamic West Conshohocken, Pennsylvania region.
Madrigal Pharmaceuticals's ticker is MDGL
The company's shares trade on the NASDAQ stock exchange
They are based in Conshohocken, Pennsylvania
There are 11-50 employees working at Madrigal Pharmaceuticals
It is madrigalpharma.com
Madrigal Pharmaceuticals is in the Healthcare sector
Madrigal Pharmaceuticals is in the Biotechnology industry
The following five companies are Madrigal Pharmaceuticals's industry peers: